病毒載體相關共同研究及授權契約:2016年～2025年

本報告全面解讀了全球領先生物製藥公司簽署的病毒載體協議，並提供了前所未有的存取權限。

本報告詳細解讀並分析了公司簽署病毒載體協議的方式和原因。這些協議通常涉及多個方面，通常始於合作研發，最終發展到成果商業化。

合作協議涵蓋各種類型，包括合作研發和授權協議。

本報告提供了自2016年以來已宣布的413項病毒載體相關協議的完整列表，並儘可能包含財務條款。此外，報告還提供了每項協議的在線記錄鏈接，方便您參考實際公開的協議。此外，記錄中還包含公司和/或合作夥伴向美國證券交易委員會 (SEC) 提交的合約文件（如有）。

主要優勢：

• 了解自2016年以來的交易趨勢
• 查看病毒載體的合作與授權協議
• 基準分析：確定交易的市場價值
• 詳細的財務條款：預付款、里程碑付款、特許權使用費
• 按公司名稱（A-Z）、交易類型和治療領域排序的交易目錄
• 按價值排序的熱門交易
• 最活躍的交易撮合者
• 確定每筆交易的資產和條款
• 存取合約文件：深入了解合約結構
• 盡職調查：評估擬議合約條款是否適合您的合作夥伴
• 節省數百小時的研究時間

合約分析可讓您對以下內容進行盡職調查：

• 具體授予或選擇哪些權利？
• 合約實際上賦予了合作夥伴什麼？
• 授予了哪些獨家權利？
• 合約的付款結構是怎樣的？
• 如何審計銷售和付款？
• 合約期間（生效期間）是多久？
• 合約的主要條款是如何界定的？
• 如何處理知識產權 (IPR)，由誰持有？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和成果揭露？
• 如何解決爭議？
• 合約在什麼情況下可以終止？
• 如果公司所有權發生變化，合約會怎樣？
• 如何約定再授權和分包條款？
• 公司通常會包含哪些 "範本條款" ？
• 根據合約當事人和合約類型，有哪些 "範本條款" ？
• 公司要求哪個司法管轄區作為合約法下的準據法？

目錄

摘要整理

第1章 簡介

第2章 病毒載體契約趨勢

• 各年度的病毒載體契約數量
• 最活躍的契約締結企業
• 病毒載體契約:各類型契約
• 病毒載體契約:各治療領域
• 病毒載體契約:各業界
• 病毒載體契約的交易條件

第3章 主要病毒載體契約

• 主要病毒載體契約:契約各金額

第4章 最活躍的病毒載體契約締結企業

• 最活躍的病毒載體契約締結企業
• 最活躍的病毒載體契約締結企業簡介

第5章 病毒載體契約的交易名錄

• 病毒載體契約的交易名錄

第6章 病毒載體契約:各技術類型

• 契約名錄
• 契約名錄- 各企業 (A-Z)
• 契約名錄- 各類型契約
• 契約名錄- 各治療領域
• 契約類型定義
• 關於Biopharma Research Ltd
• 目前聯盟
• 目前契約
• Current Partnering最近的報告標題

Viral Vector Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the viral vector deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of viral vector deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter viral vector deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 413 viral vector deals announced since 2016 including financial terms where available including links to online deal records of actual viral vector partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of viral vector dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in viral vector dealmaking since 2016.

Chapter 3 provides an overview of the leading viral vector deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in viral vector dealmaking with a brief summary followed by a comprehensive listing of viral vector deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of viral vector deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of viral vector partnering deals signed and announced since Jan 2016. The chapter is organized by specific viral vector technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in viral vector deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Viral Vector Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse viral vector collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Viral Vector Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of viral vector trends and structure of deals entered into by leading biopharma companies worldwide.

Viral Vector Collaboration and Licensing Deals includes:

• Trends in viral vector dealmaking in the biopharma industry
• Directory of viral vector deal records covering pharmaceutical and biotechnology
• The leading viral vector deals by value
• Most active viral vector licensing dealmakers
• Viral Vector Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in viral vector dealmaking

• 2.1. Introduction
• 2.2. Viral vector deals over the years
• 2.3. Most active viral vector dealmakers
• 2.4. Viral vector deals by deal type
• 2.5. Viral vector deals by therapy area
• 2.6. Viral vector deals by industry sector
• 2.7. Deal terms for viral vector deals
  • 2.7.1 Viral vector deals headline values
  • 2.7.2 Viral vector deal upfront payments
  • 2.7.3 Viral vector deal milestone payments
  • 2.7.4 Viral vector royalty rates

Chapter 3 - Leading viral vector deals

• 3.1. Introduction
• 3.2. Top viral vector deals by value

Chapter 4 - Most active viral vector dealmakers

• 4.1. Introduction
• 4.2. Most active viral vector dealmakers
• 4.3. Most active viral vector deals company profiles

Chapter 5 - Viral vector contracts dealmaking directory

• 5.1. Introduction
• 5.2. Viral vector contracts dealmaking directory

Chapter 6 - Viral vector dealmaking by technology type

• Deal directory
• Deal directory - Viral vector deals by company A-Z
• Deal directory - Viral vector deals by deal type
• Deal directory - Viral vector deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Viral vector deals since 2016
• Figure 2: Active viral vector dealmaking activity - 2016 - 2025
• Figure 3: Viral vector deals by deal type since 2016
• Figure 4: Viral vector deals by therapy area since 2016
• Figure 5: Viral vector deals by industry sector since 2016
• Figure 6: Viral vector deals with a headline value
• Figure 7: Viral vector deals with an upfront value
• Figure 8: Viral vector deals with a milestone value
• Figure 9: Viral vector deals with a royalty rate value
• Figure 10: Top viral vector deals by value since 2016
• Figure 11: Most active viral vector dealmakers 2016 - 2025
• Figure 12: Viral vector deals by technology type since 2016